Focus: Reflow Medical is a newly founded (2024) medical device company focused on catheter and stent systems for cardiovascular and peripheral vascular disease. The company is extremely early-stage with 1-50 employees and is currently in public status.
Profile data last refreshed 5h ago · AI intelligence enriched 2mo ago
Hot — 23 jobs added in 30d
Net +23 (23 new, 0 removed). Aggressive expansion phase.
Reflow Medical offers high-risk, high-reward early-stage opportunity best suited for risk-tolerant professionals seeking startup equity upside and functional diversity, but financial viability and long-term prospects remain unvalidated.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Reflow Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Reflow Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Reflow Medical has positive data for coronary drug-eluting stent - MassDevice
Reflow Medical has positive data for coronary drug-eluting stent MassDevice
Reflow Medical announces 12-month results from DEEPER REVEAL trial - Vascular News
Reflow Medical announces 12-month results from DEEPER REVEAL trial Vascular News
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Early Tibial Vessel Recoil Following Treatment With the Bare Temporary Spur Stent System: Results From the DEEPER OUS Vessel Recoil Substudy.
Preclinical Evaluation of the Temporary Drug-Coated Spur Stent System in Porcine Peripheral Arteries.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo